Logo
SubscribeSign In
LeaderPortfolio
Billionaire Profile
P
Global Rank
#1030

Image: Rodríguez, Juan María Academia de Medicina de México (1871-1887) | Public domain | via Wikimedia Commons

Pablo Legorreta

CEO, Royalty Pharma
UNITED STATES
Real-Time Net Worth
$4.067B
Estimated based on Royalty Pharma stock value as of March 6, 2026
-1.05% (24h)
Age
62
Source
Investments
Industry
finance-investments
Citizenship
UNITED STATES

Biography

Pablo Legorreta is a Mexican-American billionaire businessman, best known as the founder and CEO of Royalty Pharma, the world's largest acquirer of pharmaceutical royalty streams. Born in 1963/1964, Legorreta has built a career focused on investments within the biopharmaceutical sector. He earned a Bachelor of Science in Engineering from Universidad Iberoamericana. Legorreta's source of wealth stems from his investments, particularly in Royalty Pharma, which has generated revenue from blockbuster drugs like Humira, Imbruvica, and Lyrica. As of February 2, 2026, his estimated net worth is $3.8 Billion. His investment strategy has revolutionized the acquisition and management of pharmaceutical royalties, making him a significant figure in the finance-investments industry.

Fact Checked
Verified by Editorial Team
Live Data
Updated 3/6/2026

Wealth Over Time

In-Depth Profile

Early Life

Pablo Legorreta was born in Mexico in 1963/1964. Specific details about his early life are not widely available. He earned a Bachelor of Science in Engineering from Universidad Iberoamericana in 1985.

Rise to Success

Legorreta's career began in investment banking. He worked at Lazard Frères, doing mergers and acquisitions between Paris and New York, rising to vice president. In 1996, at the age of 32, he founded Royalty Pharma. Royalty Pharma pioneered royalty funding in life science innovation. The company has deployed more than $25 billion of capital to advance innovation in the biopharmaceutical industry. In 2020, Royalty Pharma went public.

Key Business Strategies

Royalty Pharma's business model involves acquiring royalty interests in late-stage biopharmaceutical products. The company does not discover, develop, manufacture, or market the products, but instead invests in the royalty streams of successful drugs. Legorreta's strategy has been to provide non-dilutive capital to innovators, creating a diverse portfolio of revenue-generating biopharmaceutical products.

Philanthropy

Legorreta founded Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and healthcare providers with continued education opportunities.

Career Milestones

1996

Founded Royalty Pharma

Established Royalty Pharma, a company focused on acquiring pharmaceutical royalty streams.

2020

Royalty Pharma IPO

Took Royalty Pharma public, which valued the company at $16.7 billion.

Philanthropy & Social Impact

Healthcare

Alianza Médica para la Salud

Not Available

A non-profit dedicated to enhancing the quality of health care in Latin America.

Business Philosophy & Leadership

Leadership Principles

Focus on Innovation

Investing in and supporting innovation in the life sciences industry is key to success.

Win-Win Partnerships

Creating mutually beneficial relationships with academic institutions and other partners.

Compare Pablo Legorreta

Net Worth Face-off
Pablo Legorreta vs Elon Musk
Compare Wealth →
Net Worth Face-off
Pablo Legorreta vs Jeff Bezos
Compare Wealth →
Net Worth Face-off
Pablo Legorreta vs Mark Zuckerberg
Compare Wealth →